title: Evaluation of a synthetic CArG promoter for nitric oxide synthase gene therapy of cancer.
abstract: Nitric oxide synthase gene therapy has been shown to be effective at inducing apoptosis in experimental tumours and sensitizing them to radiotherapy. We have also shown that expression of inducible nitric oxide synthase (iNOS) can be effectively restricted to the tumour volume by the use of the radiation inducible promoter (WAF1) to drive the transgene in clinically relevant protocols. A synthetic construct (pE9), incorporating nine radiosensitive CArG elements from the Egr1 promoter, has recently been developed for cancer gene therapy. We have now investigated basal gene expression of transgenes driven by this promoter to assess its suitability for use in iNOS gene therapy protocols in vivo. Transfection of human microvascular endothelial cells (HMEC-1) with pE9iNOS, using a cationic lipid vector, resulted in progressively increasing (<5-fold) levels of iNOS protein expression up to 8 h after transfection. Transfection of an ex vivo rat artery preparation with pE9iNOS caused 83% inhibition of response to the vasoconstrictor phenylephrine (PE). CMViNOS transfection also reduced response to PE, but by only 52%. A single injection of 25 microg of pE9iNOS DNA in a lipid vector into the centre of a murine sarcoma (RIF1) induced iNOS protein expression by four-fold and increased nitrite concentration eight-fold. This caused a 7-day delay in tumour growth and was more effective than the constitutive CMV-driven construct. Our data suggest that generation of NO*, as a result of iNOS overexpression, is capable of further activating the E9 promoter, through a positive feedback loop, yielding stronger and sustained levels of NO*. This pE9iNOS combination may, therefore, be particularly useful in an anticancer gene therapy strategy as its antitumour effect in vivo was clearly superior to that of the strong constitutive promoter, CMV.
authors.affiliation: School of Biomedical Sciences, University of Ulster, Coleraine, Co. Londonderry, UK.
authors.forename: J
authors.initials: J
authors.lastname: Worthington
authors.forename: T
authors.initials: T
authors.lastname: Robson
authors.forename: S
authors.initials: S
authors.lastname: Scott
authors.forename: D
authors.initials: D
authors.lastname: Hirst
mesh_terms: D000818:Animals; D015153:Blotting, Western / Q000379:methods; D002460:Cell Line; D003587:Cytomegalovirus / Q000235:genetics; D004790:Enzyme Induction; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D009374:Neoplasms, Experimental; D009569:Nitric Oxide / Q000032:analysis; D052247:Nitric Oxide Synthase Type II / Q000235:genetics* / Q000378:metabolism; D010714:Phosphatidylethanolamines; D011401:Promoter Regions, Genetic; D051381:Rats; D017208:Rats, Wistar; D014161:Transduction, Genetic / Q000379:methods; D014162:Transfection / Q000379:methods*; D019076:Transgenes
chemical_list: D010714:Phosphatidylethanolamines; D009569:Nitric Oxide; C020888:1,2-dielaidoylphosphatidylethanolamine; D052247:Nitric Oxide Synthase Type II